Advertisement covers CROI 2014

What Major HIV Research Developments Does 2014 Hold in Store?

April 4, 2014


Tim Horn

Long-Acting HIV Treatment

"I think one of the most exciting things that we're seeing here is a presentation from the LATTE study, which is actually taking a look at switching from a combination of three drugs to a combination of two drugs in oral versions of GSK744, which is an integrase inhibitor, plus oral rilpivirine, which is a currently improved NNRTI (non-nucleoside reverse transcriptase inhibitor).

"What's really important about this study is that documenting the efficacy of those two drugs to maintain viral load suppression will allow us to conduct another study, which will be looking at long-acting versions of those agents, which are basically liquid formulations. They're nano-suppression formulations which will be infused intramuscularly and administered only once a month.

"So we need to see that these two drugs being used together can maintain viral load, which is really a groundbreaking study looking at the use of long-acting drugs to maintain viral load suppression in people living with HIV."

-- Tim Horn, HIV Project Director, Treatment Action Group.

This article was provided by It is a part of the publication The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014).


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.